Varicella Seroprevalence in Healthcare Workers at a Medical Center Following Changes in National and Local Hospital Vaccination Policies

Meng-Ting Tsou * and Hsin-Hui Shao

The Department of Family Medicine, Mackay Memorial Hospital, Taipei City 10449, Taiwan;
chocosophi@gmail.com

* Correspondence: mttsou@gmail.com; Tel: +886-2-25433535 (ext. 2131 or 2132)

Received: 28 August 2019; Accepted: 20 September 2019; Published: 22 September 2019

Abstract: Background: Varicella seroprevalence in healthcare workers at a tertiary care hospital in Taiwan was assessed following the inclusion of varicella zoster vaccination in the national vaccination schedule in 2004 and was made a hospital policy in 2008. Methods: Seroprevalence data were extracted from records of pre-employment health check-ups performed between 2008 and 2018 at a single medical center. Staff with complete medical records and anti-varicella zoster virus immunoglobulin G (VZV IgG) titers were included. Sex and age group differences in terms of geometric mean titer (GMT) were compared using analysis of variance and chi-squared tests. The significance of the correlation between age and the anti-VZV IgG titer was tested by linear regression. The odds of significant associations among age, sex, vocation, and the years of national and hospital adoption of vaccination were determined using univariate and multivariate analyses. Results: Of the 7314 eligible participants, 5625 (76.90%) were women, and the mean patient age was 26.80 ± 8.00 years. The lowest VZV-positivity rates were in 18–20-year-old women (85.16%; GMT, 362.89 mIU/mL) and men (87.59%; GMT, 288.07 mIU/mL). VZV positivity increased with age (p < 0.001). Participants born before 2002 were more likely to be seropositive than those born after 2003 (odds ratio, 2.51 vs. 1.0; p < 0.001). The lowest seropositive rate was found in the nursing staff (88.91%; 95% confidence interval, 87.74%–90.05%). Varicella vaccine boosters have been required at pre-employment health check-ups since 2008 if anti-VZV antibodies were not detectable. A follow-up evaluation found marginal significant differences in the odds ratios of seropositivity after 2007 (p = 0.052), especially in 2008 and 2014 (p < 0.05) after the hospital policy launched. Conclusions: Despite public health efforts, a small number of healthcare workers were inadequately protected, and antibody titers were lower than required to maintain herd immunity. For effective prevention of nosocomial infection, VZV IgG status should be documented for all HCWs, and susceptible HCWs should be vaccinated to avoid outbreaks. Pre-employment screening and vaccination have increased immunity and need to be conducted to ensure protection of vulnerable patients.

Keywords: healthcare worker; seroprevalence; varicella; immunization

1. Introduction

It is important that the immunity of the hospital staff to varicella zoster virus (VZV) be monitored in order to decrease the risk of nosocomial infection and infection to the staff and visitors [1,2]. Varicella is highly contagious and spreads via respiratory aerosols or vesicle fluid. It is usually self-limiting but may cause severe complications [2–4]. Approximately 11,000 cases of varicella are reported per year in Taiwan [5]. Free VZV vaccination of children aged >1 year was adopted in
2004 [5]. After national policy for vaccination, its incidence in infants and young children has fallen sharply, but the outbreaks of varicella infection may occur in adults as the anti-VZV antibody titer falls. The estimated varicella-associated hospitalization rate is 60 per 1000 patients and is highest among those aged 19–38 or >75 years [5,6]. Therefore, a national recommendation of vaccination for susceptible healthcare workers (HCWs) has been made but not yet implemented owing to the costs of testing and vaccine administration. Several outbreaks of nosocomial varicella infection have occurred in recent years [7]. Because preventing and managing nosocomial varicella is costly, vaccination of HCWs without immunity may be the most cost-effective strategy [8–12].

Our hospital began routine pre-employment screening of all staff in 2008, with varicella vaccine boosters required for anyone with undetectable antibody titers. Self-reported histories of varicella infection (including native or occupational exposure) are not accepted to avoid vaccination; only serology data are considered. This study assessed the varicella seroprevalence among HCWs after the implementation of national and hospital HCW vaccination policies in Taiwan to help guide the development of a local screening program.

2. Methods

2.1. Study Center and Population

The study was performed at Mackay Memorial Hospital, a 2000-bed tertiary care hospital in Northern Taiwan, a region with an estimated population of 2.67 million. The study data were retrieved from routine pre-employment health check-ups of HCWs conducted between January 2008 and June 2018 that included screening of VZV antibodies. Inclusion criteria: (1) Age was greater than or equal to 18 years old (the legal age of majority); (2) Full-time HCWs. There were no special exclusion criteria because pre-employment health check-ups are the routine examination by government law, and HCWs needed to finish the vaccination and get the certification before they joined the workplace. There was no sampling in this study. All HCWs were explained the main goal of this research before obtaining an informed consent. The sample size was estimated including six age groups (18–20, 21–30, 31–40, 41–50, 51–60, and 61–70 years of age) and assuming a 5% error in the seroprevalence data and a confidence interval (CI) of 95%. The age ranges were established in relation to a target cohort of VZV vaccine recipients included in the universal mass vaccination of all newborns in 2003. Older subjects were enrolled to compare the seroepidemiology of varicella in the pre- and post-vaccination eras. HCW categories included doctors (physician, surgeon, specialist, dentist, traditional Chinese physician), nurses (emergency department, outpatient clinic), examination department (laboratory, ultrasound, endoscopy, catherization), preventive and long-term care services (physical examination center, community medicine division, nursing home, daycare center), and administration.

2.2. Laboratory Values

A 5 mL serum sample was collected from each participant for determination of anti-varicella zoster virus immunoglobulin G (anti-VZV IgG) with a quantitative varicella IgG enzyme-linked immunosorbert assay of known sensitivity (98.42%, 95% CI = 96.25%–99.31%) and specificity (93.94%, 95% CI = 79.83%–99.34%). A concentration ≥165 mIU/mL was considered reactive (positive). Tests with borderline results (135–165 mIU/mL) were repeated.

2.3. Statistical Analysis

Participant age, sex, and laboratory results were entered into a FileMaker Pro (www.filemaker.com) database and analyzed by SPSS (IBM Corp., Armonk, NY, USA). Age and sex differences in the geometrical mean anti-VZV IgG titers (GMTs) were compared with Student’s t-test or analysis of variance. Chi-squared tests were used to compare differences in the proportions of anti-VZV IgG positive participants. The significance of correlations of age and anti-VZV IgG titer was determined by linear regression analysis. Univariate and multiple logistic regression analysis was used to
determine the odds of immunity following VZV exposure associated with age, sex, vocation, the year of government and hospital vaccination policy. \( p \)-values of <0.05 were considered significant.

2.4. Ethical Certification

The study was certificated by the Ethics Committee of Mackay Memorial Hospital (No. 18MMHIS103).

3. Results

VZV seroprevalence was assessed in 7314 participants between 2008 and 2018 during the annual pre-employment health screening (power = 0.8, \( \alpha = 0.05 \), \( \beta = 0.2 \)). The mean age was 26.80 ± 8.00 (18–68) years, 5625 (76.90%) participants were women, and the men were older than the women (28.14 ± 6.98 vs. 26.40 ± 8.23; \( p < 0.001 \)). The characteristics of the men and women in each age group are shown in Table 1. The anti-VZV IgG titer was \( \geq 165 \text{ mIU/mL} \) in 6629 participants (90.63%, 95% CI: 89.72–91.87) of the participants. The percentage was higher in men (n = 1549/1689; 91.71%; 95% CI: 90.72–92.66) than in women (n = 5080/5625; 90.31%, 95% CI: 89.25–91.57; \( p < 0.001 \)). In the age groups (Figure 1), 757/885 participants (85.54%, 95% CI: 83.22–87.86) from 18–20, 4330/4778 participants (90.62%, 95% CI: 89.79–91.45) from 21–30, 1011/1092 participants (92.58%, 95% CI: 91.03–94.14) from 31–40, 380/400 participants (95.00%, 95% CI: 92.86–97.14) from 41–50, 122/130 participants, (93.85%, 95% CI: 89.72–97.98) from 51–60, and all 29 (100%) of those from 61–70 years of age were seropositive (\( p < 0.001 \)). The mean anti-VZV IgG titer was 542.90 mIU/mL and was higher in men (563.14 mIU/mL) that in women (547.49 mIU/mL, \( p < 0.001 \)). The sex difference persisted when the analysis included the age groups (women F = 33.23, men F = 18.31; \( r^2 = 0.01, p < 0.001 \)). There was significant correlation between age and anti-VZV IgG titer in both women (\( r^2 = 0.006 \)) and men (\( r^2 = 0.01, p < 0.001, \) Figure 1).

![Figure 1](image-url)

**Figure 1.** Proportion of varicella zoster immunoglobulin G (IgG)-positive subjects and varicella zoster IgG geometric mean titer (GMT), by age group and gender. Orange columns: % of varicella zoster IgG-positive females (\( p < 0.001 \)). Blue columns: % of varicella zoster IgG-positive males (\( p = 0.310 \)).

Yellow line: Varicella zoster IgG GMT in females (\( p < 0.001 \)). Gray line: Varicella zoster IgG GMT in males (\( p < 0.001 \)) (Chi-squared test; linear regression).
Table 1. Distribution of enrolled subjects by gender.

| Age Group | Female | Male | Total |
|-----------|--------|------|-------|
|           | n      | %    | n     | %    | n     | %    |
| 18–20     | 748    | 13.30| 137   | 8.11 | 885   | 12.10|
| 21–30     | 3632   | 64.57| 1146  | 67.85| 4778  | 65.33|
| 31–40     | 787    | 13.99| 305   | 18.06| 1092  | 14.93|
| 41–50     | 330    | 5.87 | 70    | 4.14 | 400   | 5.47 |
| 51–60     | 112    | 1.99 | 18    | 1.07 | 130   | 1.78 |
| 61–70     | 16     | 0.28 | 13    | 0.77 | 29    | 0.40 |
| Total     | 5625   | 1689 | 7314  |      |       |      |

Chi-square = 66.426; \( p < 0.0001 \).

The seroprevalence estimates and their 95% CIs for the various healthcare providers (vocations) are shown in Table 2. Multiple logistic regression of immunity status (Table 3) found no significant difference in the odds of immunity in male and female employees. Young employees were significantly less likely to be immune, and those who were more than 50 years of age had higher odds of immunity than elderly employees \( (p < 0.001) \). The adjusted odds of immunity were significantly lower for employees born in recent decades. Nursing and administrators were significantly less likely to be seropositive than employees in other vocations \( (OR = 0.58–0.69, p < 0.001) \). Since 2008, varicella zoster seropositivity has been assayed in hospital employees, and boosters are required for those with undetectable antibody titer. The odds ratio calculation found marginal significant differences in immunity after/before 2007 \( (p = 0.052) \), especially in 2008 and in 2014 \( (p < 0.05) \) after the booster vaccination policy was implemented, (Table 4).

Table 2. Crude seroprevalence by vocation \( (n = 7314) \).

| Vocation                              | Age (Years) (Mean ± SD) | \( p \)-Value | n   | Seroprevalence in % (Binominal 95% CI) | \( p \)-Value |
|---------------------------------------|-------------------------|--------------|-----|---------------------------------------|--------------|
| Nurses                                | 24.82 ± 0.42            | <0.001       | 2826| 88.9 (87.7–90.0)                      | <0.001       |
| Doctors                               | 27.74 ± 0.38            |              | 1394| 92.8 (91.4–94.2)                      |              |
| Examination                          | 27.97 ± 0.12            |              | 481 | 93.2 (91.0–95.4)                      |              |
| Preventive and long-term care service | 33.06 ± 0.24            |              | 226 | 91.5 (87.9–95.1)                      |              |
| Administration                        | 25.87 ± 0.13            |              | 1702| 91.0 (89.6–92.4)                      |              |

Table 3. Multiple logistic regression of immune status after national policy \( (n = 7314) \).

| Variable   | Odds Ratio | \( p \)-Value | 95 % CI   |
|------------|------------|---------------|-----------|
|            |            |               | Lower     | Upper     |
| Gender     |            |               |           |           |
| Female     | 1.000      | -             | -         | -         |
| Male       | 0.968      | 0.775         | 0.774     | 1.210     |
| Birth-group|            |               |           |           |
| After 1 January 2003 | 1.000      | -             | -         | -         |
| Before 31 December 2002 | 2.506      | <0.001        | 1.902     | 3.515     |
| Age-group  |            |               |           |           |
| 18–20      | 1.000      |               |           |           |
| 21–30      | 1.703      | <0.001        | 1.349     | 2.151     |
| 31–40      | 2.406      | <0.001        | 1.683     | 3.438     |
| 41–50      | 5.551      | <0.001        | 2.671     | 11.536    |
| 51–60      | 5.734      | <0.001        | 2.261     | 14.542    |
| 61–70      |            |               |           |           |
Table 3. Cont.

| Variable                        | Odds Ratio | p-Value | 95 % CI      |
|---------------------------------|------------|---------|--------------|
| Vocation                        |            |         |              |
| Doctors                         | 1.000      | -       | -            |
| Nurses (ER, clinics)            | 0.579      | 0.001   | 0.414 0.811  |
| Nurses (wards)                  | 0.661      | 0.002   | 0.507 0.861  |
| Examination                     | 0.975      | 0.902   | 0.650 1.462  |
| Preventive and long-term care service | 0.747      | 0.259   | 0.450 1.240  |
| Administration                  | 0.690      | 0.006   | 0.531 0.898  |

Table 4. Univariate logistic regression of immune status after hospital policy (n = 7314).

| Year               | Odds Ratio | p-Value | 95 % CI      |
|--------------------|------------|---------|--------------|
| Year               |            |         |              |
| (a) 2003–2007 (before policy) | 1.000      | -       | -            |
| 2008–2018 (after policy)       | 1.456      | 0.052   | 0.967 2.345  |
| (b) 2003–2007 (before policy) | 1.000      | -       | -            |
| 2008                | 2.036      | 0.046   | 1.283 4.216  |
| 2009                | 1.538      | 0.233   | 0.758 3.121  |
| 2010                | 1.392      | 0.361   | 0.685 2.829  |
| 2011                | 1.545      | 0.226   | 0.764 3.126  |
| 2012                | 1.577      | 0.207   | 0.777 3.199  |
| 2013                | 1.852      | 0.098   | 0.893 3.844  |
| 2014                | 2.088      | 0.049   | 1.100 4.360  |
| 2015                | 1.774      | 0.119   | 0.863 3.645  |
| 2016                | 1.477      | 0.288   | 0.720 3.028  |
| 2017                | 1.234      | 0.564   | 0.604 2.519  |
| 2018                | 1.056      | 0.889   | 0.491 2.271  |

4. Discussion

This was the first study to document the effects of national and hospital vaccination policies on VZV seroprevalence in HCWs in Taiwan. VZV seropositivity was 90.63%, which is consistent with the 91.1% previously reported in Taiwan [7]. It has been reported that a group immunity of 94% or more is needed to interrupt viral transmission in the healthcare setting [2,13]. The study results showed a lack of VZV immunity in young participants 18–20 years of age, in whom nearly 15% were not seropositive. The percentage was less than 10% in other age groups. VZV seropositivity rate in the HCWs in this hospital may not be sufficiently high to prevent outbreaks of varicella; interventions to prevent varicella transmission are desirable.

Free VZV vaccination of children >1 year of age has been included in the national vaccination schedule in Taiwan since 2004 [5]. Varicella is now a preventable disease in Taiwan, and its incidence in infants and young children has fallen sharply. The hospital records show that varicella infection decreased by 82% in 2004 and 72% in 2012 [6]. The durability of the protection provided by vaccine-induced antibodies is limited, and outbreaks of varicella infection may occur in adults as the anti-VZV antibody titer falls. The hospitalization rate of adults with varicella is approximately 44.1 per 1000 people, which is much higher than that of young varicella patients (10.4 per 1000 people) [6]. Logistic regression analysis of the 2018 data found that staff born before 2002 had significantly higher odds of being immune than those born after 2003. Our crude annual seroprevalence estimates were in keeping with the reported national rates for adults, which ranged from 88.3% at 11–20 and 99.6% at >65 years of age [14]. The available epidemiological data indicate that 90%–95% of the general population was infected by VZV before adulthood and that about 5%–10% of adults are susceptible to
infection [15]. GMTs generally increased with age but fell between 560–700 IU/mL in 2–5-year-olds. The titer in those older than 13 years of age was >1000 IU/mL, indicating that the antibody titer induced by natural infection was significantly higher than that induced by vaccination [6]. As the incidence of disease continues to decrease, the chance of exposure to VZV will decrease. In the absence of a natural booster, the protection provided by early childhood vaccination may decrease in adolescence and adulthood. That may result in an increase of varicella complications in addition to the risk HCW infection [2,6].

The overall hospital-wide laboratory-confirmed seroprevalence of 90.63% (95% CI 89.81–91.89) in this study is comparable to the 91.1% previously reported by another hospital in Taiwan and the 92.8% reported by a Singapore hospital [7,16]. The seroprevalence rates in this study were lower than those reported by Japanese healthcare institutions, which ranged from 94.7% to 97.4% [17–19]. Data on HCWs in the wider Southeast Asian region are not available for comparison except for a small sample studied in Malaysia, which had a seroprevalence of 84.4% [20].

Routine surveillance of anti-VZV titers was implemented for the staff at this medical center in 2008, with boosters required for all HCWs with undetectable antibody titers. The seroprevalence rates after/before 2007 were marginally significantly different after the vaccination policy changed. Follow-up testing of varicella IgG titers was done 1 month after booster administration following the healthcare personnel vaccination recommendations at this hospital [15]. Between 70% to 90% adults given two doses of varicella vaccine 4–8 weeks apart are expected to develop protective antibodies, and the antibody titer can be only maintained for 7–10 years, not lifelong [1]. Whether additional vaccinations are needed later is subject to further observation [15,20].

Past hospital policy provided free vaccination of HCWs in conjunction with outbreak investigations and annual screening. The significant increase in seroprevalence recorded since 2008 coincided with a change in the pre-employment policy implemented in the previous year that required new employees to be serologically screened and vaccinated. In this study, the observation that administrative and nursing staff were less likely to be immune than doctors is in keeping with previous national vaccination policies that resulted in lower immunity in younger staff members. In this study, nurses and administrators were younger than the other HCWs. The results were similar to those of a previous study in Singapore in which administrative staff and service providers were less likely to be seropositive than older HCWs [16]. Varicella is an airborne infection that does not discriminate between vocations [4]. Consequently, both clinical and nonclinical members of the workforce are vaccinated at this hospital.

The interventions of the infection control department in hospital could help to build increased trust in the effectiveness and safety of vaccines and in the vaccine policy, ultimately enhancing the contribution of all staff to increase vaccination rates and build vaccine acceptance and resiliency in the face of the anti-vaccine lobby in HCWs and, subsequently, in the general population [21]. The hospital director must recognize the importance and impact of a successful HCW vaccine policy, distinguishing “forced vaccination, free vaccination, and convenient vaccination” and including a systematic tracking plan [15].

To prevent the transmission of varicella to healthcare workers, according to the Advisory Committee on Immunization Practices (ACIP)/Centers for Disease Control and Prevention (CDC), whom recommend that all healthcare workers (HCWs) be immune to VZV [1,22,23]. Therefore, the first step in the prevention of healthcare-associated transmission of VZV in a local screening program is to minimize the number of susceptible HCWs [12,24]. The history of vaccination or immunity for VZV should be determined at the time of initial employment in all HCWs. Serologic screening, such as VZV IgG, before vaccination is indicated for persons with no or uncertain history of varicella [21,25,26].

This study has several limitations and should be interpreted with caution. Firstly, it included only HCWs from a single hospital. The results may not be generalizable to HCWs at other hospitals in Taiwan. Nevertheless, this is the first study to evaluate varicella immunity after the implementation of national and HCW vaccination. The study population was large and comprised all HCWs regardless of job title. Ultimately, the findings will help to guide the development of a local policy to identify
HCWs who are no longer immune and to develop immunization recommendations. Secondly, we did not evaluate the duration of HCWs’ occupational history, the possibility of longer occupational history provided more opportunities to reinforce their immunization status. Thirdly, Some HCWs were found to be seronegative 1 month after two doses of VZV vaccine. We did not follow up after 6 months because according to the recommendation from ACIP: Post-immunization serology is not recommended since: 1. Commercial tests may lack the sensitivity to detect the lower antibody levels associated with vaccination compared with natural infection. 2. Sensitive tests that are not generally available have indicated that 92% to 99% of adults develop antibodies after two doses of varicella vaccine [21].

5. Conclusions

The varicella seropositive rate of the HCWs in this hospital was not high enough to prevent outbreaks. Evidence of immunity for HCWs includes one of the following: (1) written documentation with two doses of vaccine, (2) laboratory evidence of immunity or laboratory confirmation of disease, (3) diagnosis or verification of history of varicella or herpes zoster by a healthcare provider [2]. Confirmation of the VZV IgG status of all HCWs and the vaccination of those who are susceptible is recommended for effective prevention of nosocomial varicella infections. A review of 10 years of data revealed that some elements of the workforce benefited from pre-employment screening and vaccination. Future studies should include evaluation of immunization records to determine whether immunity has been acquired naturally or by vaccination. In addition to mandatory vaccination of new employees, we want to decrease the residual population who are not immune to varicella. Those individuals are at risk of infection and pose an infection risk to our patients and are vulnerable to complications of varicella. We have achieved improvements in seropositivity but more needs to be done to ensure that staff, patients, and hospital visitors are protected from this vaccine-preventable disease.

Author Contributions: M.-T.T.: Conception and design, provision of study materials of patients, collection and assembly of data, data analysis and interpretation, article writing, review and editing. H.-H.S.: Conception and design, provision of study materials of patients.

Funding: No funding was received.

Acknowledgments: The authors would like to acknowledge all staff who were invested in finishing annual health screenings.

Conflicts of Interest: The author declares no conflict of interest.

Abbreviations

VZV IgG Varicella zoster virus immunoglobulin G
GMT Geometric mean titer
HCWs Healthcare workers
OR Odds ratio
CI Confidence interval
ACIP Advisory Committee on Immunization Practices
CDC Centers for Disease Control and Prevention

References

1. Advisory Committee on Immunization Practices, and Centers for Disease Control and Prevention. Immunization of health-care personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Morb Mortal Week Rep. Recomm. Rep. 2011, 60, 1.
2. Yang, J.; Liu, J.; Xing, F.; Ye, H.; Dai, G.; Liu, M.; Lo, S.K.F.; Lau, R.W.T.; Chiu, K.H.Y.; Chan, J.F.W.; et al. Nosocomial transmission of chickenpox and varicella zoster virus seroprevalence rate amongst healthcare workers in a teaching hospital in China. BMC Infect. Dis. 2019, 19, 582–589. [CrossRef] [PubMed]
3. Holmes, C.N. Predictive value of a history of varicella infection. Can. Fam. Phys. 2005, 51, 60–65. [PubMed]
4. Department of Health. Notifiable Infectious Disease Statistics System; Center for Disease Control: Taipei, Taiwan, 2010.
5. Lin, Y.H.; Huang, L.M.; Chang, I.S.; Tsai, F.Y.; Chang, L.Y. Disease burden and epidemiological characteristics of varicella in Taiwan from 2000 to 2005. *J. Microbiol. Immunol. Infect.* 2009, 42, 5–12. [PubMed]
6. Promoting Routine Vaccination Against Varicella in Children from 2000 to 2012 on Epidemiology of Chickenpox in Taiwan. 2018. Available online: https://www.cdc.gov.tw/EpidemicTheme/Detail/57fKqsVWxUoUqE6f6yhmBNA?archiveld=Ja0FUZMdm79BORg9XmA (accessed on 8 July 2019).
7. Wu, M.F.; Yang, Y.W.; Lin, W.Y.; Chang, C.Y.; Soon, M.S.; Liu, C.E. Varicella zoster virus infection among healthcare workers in Taiwan: Seroprevalence and predictive value of history of varicella infection. *J. Hosp. Infect.* 2012, 80, 162–167. [CrossRef] [PubMed]
8. Apisarnthanarak, A.; Kitphati, R.; Tawatsupha, P.; Thongphubeth, K.; Apisarnthanarak, P.; Mundy, L.M. Outbreak of varicella-zoster virus infection among Thai healthcare workers. *Infect. Control Hosp. Epidemiol.* 2007, 28, 430–434. [CrossRef] [PubMed]
9. Almuneef, M.; Dillon, J.; Abbas, M.F.; Memish, Z. Varicella zoster virus immunity in multinational health care workers of a Saudi Arabian hospital. *Am. J. Infect. Control.* 2003, 31, 375–381. [CrossRef]
10. Lyznicki, J.M.; Bezman, R.J.; Genel, M. Report of the Council on Scientific Affairs, American Medical Association: Immunization of healthcare workers with varicella vaccine. *Infect. Control Hosp. Epidemiol.* 1998, 19, 348–353. [CrossRef] [PubMed]
11. CDC, USA. Immunization of health-care workers: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep.* 1997, 46, 1–42.
12. Kim, S.H.; Park, S.H.; Choi, S.M.; Lee, D.G. Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus. *J. Korean Med. Sci.* 2018, 33, e252–e265. [CrossRef] [PubMed]
13. De Juanes, J.R.; Gil, A.; San-Martin, M.; Gonzalez, A.; Esteban, J.; Garcia de Codes, A. Seroprevalence of varicella antibodies in healthcare workers and health sciences students. Reliability of self-reported history of varicella. *Vaccine* 2005, 23, 1434–1436. [CrossRef] [PubMed]
14. Long-Term National Immunity Survey 2007–2008. Available online: https://www.cdc.gov.tw/uploads/files/45d5e22c-8f0d-4928-b119-513129f9e7f6.pdf (accessed on 26 August 2019).
15. Healthcare Personnel Vaccination Recommendations. Available online: https://www.cdc.gov.tw/File/Get/c1yM2ZCMNzRxxdGxOTpJ?A (accessed on 26 August 2019).
16. Gorny, A.W.; Mittal, C.; Saw, S.; Venkatachalam, I.; Fisher, D.A.; Tambyah, P.A. Varicella seroprevalence in healthcare workers in a tertiary hospital: An audit of cross-sectional data. *BMC Res. Notes* 2015, 10, 664–771. [CrossRef] [PubMed]
17. Almuneef, M.; Memish, Z.A.; Abbas, M.E.; Balkhy, H.H. Screening healthcare workers for varicella-zoster virus: Can we trust the history? *Infect. Control Hosp. Epidemiol.* 2004, 25, 595–598. [CrossRef]
18. Santos, A.M.; Ono, E.; Weckx, L.Y.; Coutinho, A.P.; de Moraes-Pinto, M.I. Varicella zoster antibodies in healthcare workers from two neonatal units in Sao Paulo, Brazil: An assessment of a staff varicella policy. *J. Hosp. Infect.* 2004, 56, 228–231. [CrossRef] [PubMed]
19. Vandersmissen, G.; Moens, G.; Vranckx, R.; de Schryver, A.; Jacques, P. Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: A seroprevalence study. *Occup. Environ. Med.* 2000, 57, 621–626. [CrossRef] [PubMed]
20. Havari, S.; Bénét, T.; Saadatian-Elahi, M.; André, P.; Louergue, P.; Vanhems, P. Vaccination of healthcare workers: A review. *Hum. Vaccin. Immunoother.* 2015, 11, 2522–2537. [CrossRef]
21. Riccio, M.; Cattani, S.; Casagrande, F.; Gualerzi, G.; Signorelli, C. Knowledge, attitudes, beliefs and practices of occupational physicians towards vaccinations of health care workers: A cross sectional pilot study in North-Eastern Italy. *Int. J. Occup. Med. Environ. Health* 2017, 30, 775–790. [CrossRef]
22. David, J.W.; Martin, S.H.; Jennifer, M. Prevention and control of varicella-zoster virus in hospitals. Available online: https://www.uptodate.com/contents/prevention-and-control-of-varicella-zoster-virus-in-hospitals (accessed on 10 September 2019).
23. Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2007, 56, 1.
24. Weber, D.J.; Rutala, W.A. Occupational health update: Focus on preventing the acquisition of infections with pre-exposure prophylaxis and postexposure prophylaxis. *Infect. Dis. Clin.* 2016, 30, 729–757. [CrossRef]
25. Nettleman, M.D.; Schmid, M. Controlling varicella in the healthcare setting: The cost effectiveness of using varicella vaccine in healthcare workers. *Infect. Control Hosp. Epidemiol.* 1997, 18, 504–508. [CrossRef]

26. O’Neill, J.; Buttery, J. Varicella and paediatric staff: Current practice and vaccine cost-effectiveness. *J. Hosp. Infect.* 2003, 53, 117–119. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).